bodipy-cyclopamine

MRT 10 是一种七跨膜平滑受体 (Smo) 拮抗剂，通过多种 Hedgehog (Hh) 测定，其IC50=0.65 μM。它与Smo 受体结合的位点是 Bodipycyclopamine。它可用于研究癌症。

MRT-81 是一种人和啮齿动物 smoothened 受体的有效拮抗剂，能够抑制 hedgehog 的活性，在 Shh-light2 细胞中的IC50值为 41 nM。它可用于研究癌症。

Purmorphamine (Shh Signaling Antagonist VI) 是平滑受体激动剂，EC50为 1 μM。它阻止 BODIPY-cyclopamine 与 Smo 结合。它也是成骨细胞分化的诱导剂。

BMS-833923 (XL-139) 是一种口服生物可利用的 Smoothened 拮抗剂，以剂量依赖性方式抑制 BODIPY cyclopamine 与 SMO 的结合，IC50为21 nM。

MRT-83 (hydrochloride) is a potent antagonist of the Smoothened (Smo) receptor, effectively inhibiting the Hedgehog (Hh) signaling pathway and BODIPY-cyclopamine binding to human Smo. With its potential applications in the study of cancer disease, MRT-83 (hydrochloride) demonstrates promising prospects for research purposes.

Cyclopamine-KAAD is a potent inhibitor of hedgehog signaling with an IC50 value of 20 nM in a Shh-LIGHT2 assay. It blocks binding of BODIPY-cyclopamine to cells expressing Smoothened (Smo) in a dose-dependent manner. Cyclopamine-KAAD is cell-permeable and binds to SmoA1 to promote its exit from the endoplasmic reticulum. It inhibits the invasion and migration (45.9 and 43.3% inhibition, respectively) of Bel-7402 hepatocarcinoma cells and decreases the expression of nuclear glioma-associated oncogene 1 (Gli1) and cytosolic MMP-9, pERK1, and pERK2 proteins in a dose-dependent manner. Cyclopamine-KAAD also increases TRAIL-mediated cell death in NCH82 and NCH89 human glioblastoma cultures and upregulates expression of the death receptors DR4 and DR5 in LN229 and U251 glioma cells.